Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer

Antonino Cassata, Giuseppe Procopio, Massimiliano Alù, Leonardo Ferrari, Erminia Ferrario, Elena Beretta, Raffaella Longarini, Giuseppina Busto, Daniela De Candis, Emilio Bajetta

Research output: Contribution to journalArticle

Abstract

Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.

Original languageEnglish
Pages (from-to)364-371
Number of pages8
JournalTumori
Volume87
Issue number6
Publication statusPublished - 2001

Fingerprint

Fluorouracil
Colorectal Neoplasms
Dihydrouracil Dehydrogenase (NADP)
Breast Neoplasms
Prodrugs
Therapeutics
Intravenous Infusions
Pharmaceutical Preparations
Survival Rate
Quality of Life
Costs and Cost Analysis
Capecitabine
Neoplasms

Keywords

  • Breast neoplasms
  • Capecitabine
  • Colorectal neoplasms
  • Drug combinations
  • Fluorouracil

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cassata, A., Procopio, G., Alù, M., Ferrari, L., Ferrario, E., Beretta, E., ... Bajetta, E. (2001). Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer. Tumori, 87(6), 364-371.

Capecitabine : Indications and future perspectives in the treatment of metastatic colorectal and breast cancer. / Cassata, Antonino; Procopio, Giuseppe; Alù, Massimiliano; Ferrari, Leonardo; Ferrario, Erminia; Beretta, Elena; Longarini, Raffaella; Busto, Giuseppina; De Candis, Daniela; Bajetta, Emilio.

In: Tumori, Vol. 87, No. 6, 2001, p. 364-371.

Research output: Contribution to journalArticle

Cassata, A, Procopio, G, Alù, M, Ferrari, L, Ferrario, E, Beretta, E, Longarini, R, Busto, G, De Candis, D & Bajetta, E 2001, 'Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer', Tumori, vol. 87, no. 6, pp. 364-371.
Cassata, Antonino ; Procopio, Giuseppe ; Alù, Massimiliano ; Ferrari, Leonardo ; Ferrario, Erminia ; Beretta, Elena ; Longarini, Raffaella ; Busto, Giuseppina ; De Candis, Daniela ; Bajetta, Emilio. / Capecitabine : Indications and future perspectives in the treatment of metastatic colorectal and breast cancer. In: Tumori. 2001 ; Vol. 87, No. 6. pp. 364-371.
@article{bf0757ce20b947d1b5d1c198bc990f69,
title = "Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer",
abstract = "Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.",
keywords = "Breast neoplasms, Capecitabine, Colorectal neoplasms, Drug combinations, Fluorouracil",
author = "Antonino Cassata and Giuseppe Procopio and Massimiliano Al{\`u} and Leonardo Ferrari and Erminia Ferrario and Elena Beretta and Raffaella Longarini and Giuseppina Busto and {De Candis}, Daniela and Emilio Bajetta",
year = "2001",
language = "English",
volume = "87",
pages = "364--371",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Capecitabine

T2 - Indications and future perspectives in the treatment of metastatic colorectal and breast cancer

AU - Cassata, Antonino

AU - Procopio, Giuseppe

AU - Alù, Massimiliano

AU - Ferrari, Leonardo

AU - Ferrario, Erminia

AU - Beretta, Elena

AU - Longarini, Raffaella

AU - Busto, Giuseppina

AU - De Candis, Daniela

AU - Bajetta, Emilio

PY - 2001

Y1 - 2001

N2 - Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.

AB - Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing. Optimal administration is by continuous intravenous infusion, which makes it cumbersome to use and compromises patient independence. Recently, a number of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results. Capecitabine is the first in a new class of fluoropyrimidines. It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil. Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered intravenous 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost. Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-containing regimes for advanced colorectal and breast cancer.

KW - Breast neoplasms

KW - Capecitabine

KW - Colorectal neoplasms

KW - Drug combinations

KW - Fluorouracil

UR - http://www.scopus.com/inward/record.url?scp=0035746684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035746684&partnerID=8YFLogxK

M3 - Article

C2 - 11989587

AN - SCOPUS:0035746684

VL - 87

SP - 364

EP - 371

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -